Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ... Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ... Amsterdam, The Netherlands – – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, ...
MM&M: Takeda takes stab at CTV rare disease marketing with HyQvia campaign Takeda is making its first foray into rare disease marketing on connected TV (CTV). The Japanese biotech recently launched a video campaign for its chronic inflammatory demyelinating polyneuropathy ... Benzinga.com: Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients Argenx SE (NASDAQ:ARGX) showcased long-term data of Vyvgart (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of ... Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients
